The morphological spectrum of AFP-GC includes hepatoid adenocarcinoma, intestinal type, and signet ring cell type. The criteria for diagnosing AFP-GC depend on positive staining of the primary lesion by immunohistochemical methods.
AFP-GC has been considered as having an unfavorable long-term survival rate due in part to the higher incidence of liver metastasis and lymphovascular invasion. The cellular and molecular mechanisms responsible for its poor prognosis are not clearly understood. An early report indicated that AFP has a suppressive effect on lymphocyte transformation. 3 Another report indicated that AFP can enhance proliferative activity and increase angiogenesis due to positive expression of vascular endothelial growth factor (VEGF). 4 In a study in 2000, 5 it was found that hepatocyte growth factor (HGF) and c-met expression was higher in AFP-GC than that in AFP negative gastric cancer. Through the HGF and c-met pathway, AFP promoted tumor growth. It has been well documented that AFP-GC is quite different from the usual type of gastric cancer. It is justified to order serum AFP on all patients with gastric cancer because of its prognostic significance. To develop effective multimodal therapy against AFP-GC, a better understanding of the characteristics of AFP-GC at the cellular and molecular levels is important.
